BlackRock Health Sciences Opps R (BHSRX)

Fund Assets	6.09B
Expense Ratio	1.44%
Min. Investment	$100
Turnover	43.00%
Dividend (ttm)	n/a
Dividend Yield	n/a
Dividend Growth	n/a
Payout Frequency	Semi-Annual
Ex-Dividend Date	Jul 22, 2026

Previous Close	63.26
YTD Return	14.30%
1-Year Return	31.13%
5-Year Return	33.39%
52-Week Low	56.30
52-Week High	66.77
Beta (5Y)	0.69
Holdings	159
Inception Date	Sep 12, 2011

About BHSRX

BlackRock Health Sciences Opportunities Fund Class R is a mutual fund that focuses on investments in the health sciences and related industries. Its primary objective is to provide long-term capital growth by allocating at least 80% of its assets to equity securities of companies operating within the healthcare sector, including pharmaceuticals, biotechnology, medical devices, and healthcare services. The fund diversifies its holdings across leading names such as Eli Lilly and Company, Boston Scientific, Intuitive Surgical, AbbVie, and UnitedHealth Group, reflecting its broad exposure to both established and innovative healthcare businesses. Designed to harness the growth potential in healthcare, the fund emphasizes companies with strong scientific expertise and market leadership. Managed by BlackRock’s experienced team, the fund plays a significant role for investors seeking targeted exposure to the dynamic and essential healthcare industry. With a medium share class type suitable for retirement accounts and an investment style characterized as "Large Growth," BlackRock Health Sciences Opportunities Fund Class R is recognized for its disciplined approach and commitment to risk-adjusted returns within its sector.

• Fund Family: BlackRock
• Category: Health
• Performance Rating: Above Average
• Risk Rating: Low
• Stock Exchange: NASDAQ
• Ticker Symbol: BHSRX
• Index: Russell 3000 Healthcare TR

Performance

BHSRX had a total return of 31.13% in the past year, including dividends. Since the fund's inception, the average annual return has been 13.53%.

Top 10 Holdings

53.00% of assets

Name	Symbol	Weight
Eli Lilly and Company	LLY	12.68%
Johnson & Johnson	JNJ	7.87%
UnitedHealth Group Incorporated	UNH	6.34%
Merck & Co., Inc.	MRK	5.26%
AbbVie Inc.	ABBV	5.11%
Gilead Sciences, Inc.	GILD	3.74%
Amgen Inc.	AMGN	3.44%
Thermo Fisher Scientific Inc.	TMO	3.18%
Vertex Pharmaceuticals Incorporated	VRTX	2.89%
Edwards Lifesciences Corporation	EW	2.49%

Dividend History

Ex-Dividend	Amount	Pay Date
Jul 22, 2026	$6.46449	Jul 23, 2026
Dec 9, 2025	$2.92442	Dec 10, 2025
Jul 17, 2025	$3.83665	Jul 18, 2025
Dec 11, 2024	$3.10427	Dec 12, 2024
Jul 18, 2024	$2.49135	Jul 19, 2024
Dec 7, 2023	$0.99992	Dec 8, 2023

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Aug 26, 2026

Data Sources Report a data error